Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi & Korsinsky

Core Points - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] - The lawsuit claims that Sarepta misled investors regarding the safety and efficacy of its gene therapy product, ELEVIDYS, for Duchenne muscular dystrophy [2] Group 1 - The lawsuit seeks to recover losses for Sarepta investors who were adversely affected by the alleged fraud [1] - The complaint alleges that ELEVIDYS posed significant safety risks, and that trial protocols failed to detect severe side effects [2] - It is claimed that the severity of adverse events would lead to a halt in recruitment and dosing in ELEVIDYS trials, attracting regulatory scrutiny [2] Group 2 - Investors who suffered losses during the relevant time frame have until August 25, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] - The firm Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders [4]